Publications
Comparison of the efficacy and safety of Rituximab (Mabthera™) and its biosimilar (Reditux™) in diffuse large B-cell lymphoma patients treated with chemo-immunotherapy: A retrospective analysis
Partha Sarathi Roy 1 , Shiji John 1 , Sadashiv Karankal 2 , Sadhana Kannan 2 , Preeti Pawaskar 1 , Jayanta Gawande 1 , Bhausaheb Bagal 1 , Navin Khattry 1 , Manju Sengar 1 , Hari Menon 1 , Sumeet Gujral 3 , Reena Nair 4 Abstract
Background: Rituximab (Mabthera™) have been in use in India since 2000. A biosimilar molecule of rituximab (Reditux™) was approved in India in 2007. This retrospective audit was done to compare the efficacy and safety of Mabthera™ with Reditux™.
